Document Detail


Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
MedLine Citation:
PMID:  21665955     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Pertuzumab, a human epidermal growth factor receptor (HER) 2 dimerization inhibitor, has demonstrated promising efficacy in combination with trastuzumab in patients with metastatic breast cancer. As HER signaling pathways are not only involved in oncogenesis, but also in myocardial homeostasis, an analysis of cardiac safety data was undertaken in a large group of patients treated with pertuzumab.
PATIENTS AND METHODS: A complete database of patients treated with full-dose pertuzumab was used to describe the incidence of asymptomatic left ventricular systolic dysfunction (LVSD) and symptomatic heart failure (HF).
RESULTS: Information for 598 unique patients was available for the current analysis. Of the patients treated with pertuzumab alone (n = 331) or pertuzumab in combination with a non-anthracycline-containing cytotoxic (n = 175) or trastuzumab (n = 93), 23 (6.9%), 6 (3.4%), and 6 (6.5%), respectively, developed asymptomatic LVSD and 1 (0.3%), 2 (1.1%), and 1 (1.1%), respectively, displayed symptomatic HF. None of the 15 patients receiving both pertuzumab and erlotinib demonstrated LVSD.
CONCLUSIONS: Patients treated with pertuzumab experienced relatively low levels of asymptomatic LVSD or symptomatic HF. There was no notable increase in cardiac side-effects when pertuzumab was given in combination with other anticancer agents.
Authors:
D Lenihan; T Suter; M Brammer; C Neate; G Ross; J Baselga
Related Documents :
110955 - Evolution of the technique of home parenteral nutrition.
10549735 - Jejunal pouch to avoid stricture after esophagojejunostomy with circular stapler.
17438185 - Oral lichen planus: a case series with emphasis on therapy.
16573485 - Nutrition in the critically ill patient: part iii. enteral nutrition.
22683735 - Predicting factors associated with clinical deterioration of sepsis patients with inter...
18037845 - Prilocaine induced methaemoglobinaemia in a medically compromised patient. was this an ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-06-10
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  23     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-02-27     Completed Date:  2012-06-12     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  791-800     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, Vanderbilt University, Nashville, TN 37232, USA. daniel.lenihan@vanderbilt.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents / adverse effects*
Clinical Trials, Phase II as Topic
Heart / drug effects*
Heart Failure / chemically induced,  epidemiology*
Humans
Neoplasms / drug therapy*
Ventricular Dysfunction, Left / chemically induced,  epidemiology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 380610-27-5/pertuzumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Facilitation and Ca2+-dependent inactivation are modified by mutation of the Ca(v)1.2 channel IQ mot...
Next Document:  Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcogl...